Sofosbuvir/velpatasvir for 12 vs. 6 weeks for the treatment of recently acquired hepatitis C infection.

MLA

Matthews, Gail V., et al. “Sofosbuvir/Velpatasvir for 12 vs. 6 Weeks for the Treatment of Recently Acquired Hepatitis C Infection.” Journal of Hepatology, vol. 75, no. 4, Oct. 2021, pp. 829–39. EBSCOhost, https://doi.org/10.1016/j.jhep.2021.04.056.

APA

Matthews, G. V., Bhagani, S., Van der Valk, M., Rockstroh, J., Feld, J. J., Rauch, A., Thurnheer, C., Bruneau, J., Kim, A., Hellard, M., Shaw, D., Gane, E., Nelson, M., Ingiliz, P., Applegate, T. L., Grebely, J., Marks, P., Martinello, M., Petoumenos, K., & Dore, G. J. (2021). Sofosbuvir/velpatasvir for 12 vs. 6 weeks for the treatment of recently acquired hepatitis C infection. Journal of Hepatology, 75(4), 829–839. https://doi.org/10.1016/j.jhep.2021.04.056

Chicago

Matthews, Gail V, Sanjay Bhagani, Marc Van der Valk, Juergen Rockstroh, Jordan J Feld, Andri Rauch, Christine Thurnheer, et al. 2021. “Sofosbuvir/Velpatasvir for 12 vs. 6 Weeks for the Treatment of Recently Acquired Hepatitis C Infection.” Journal of Hepatology 75 (4): 829–39. doi:10.1016/j.jhep.2021.04.056.